1,715 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by Cassaday & Co Wealth Management LLC

Cassaday & Co Wealth Management LLC purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, Holdings Channel reports. The firm purchased 1,715 shares of the life sciences company’s stock, valued at approximately $224,000.

Several other institutional investors have also recently bought and sold shares of the business. Empowered Funds LLC raised its position in Illumina by 1.7% in the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock valued at $516,000 after buying an additional 66 shares during the last quarter. UMB Bank n.a. lifted its position in shares of Illumina by 7.0% during the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock valued at $140,000 after purchasing an additional 88 shares in the last quarter. Integrated Advisors Network LLC boosted its holdings in Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares during the last quarter. Carson Advisory Inc. grew its position in Illumina by 3.8% in the 3rd quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock worth $360,000 after purchasing an additional 102 shares in the last quarter. Finally, Huntington National Bank boosted its stake in shares of Illumina by 29.4% in the 3rd quarter. Huntington National Bank now owns 515 shares of the life sciences company’s stock worth $67,000 after buying an additional 117 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN opened at $130.74 on Tuesday. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The stock has a 50-day moving average price of $139.82 and a 200-day moving average price of $124.35. The company has a market cap of $20.74 billion, a PE ratio of -13.13 and a beta of 1.13. Illumina, Inc. has a 12-month low of $93.39 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.33 EPS. As a group, equities analysts forecast that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on ILMN shares. Barclays lifted their price target on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Argus raised shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Wednesday, August 28th. Canaccord Genuity Group raised their price target on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a research note on Tuesday, November 5th. Royal Bank of Canada boosted their price objective on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $156.00 target price on shares of Illumina in a research report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.